SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?


To: VLAD who wrote (11224)7/11/1998 11:52:00 AM
From: AlienTech  Read Replies (1) | Respond to of 23519
 
>>That article talks about the FDA being pressured to fast track approval of drugs while the sick who can be helped are dying. I never knew of a man dying from impotence and being that other ED treatments were already available, fast track approval of Viagra certainly seems strange to me.<<

You want to see some real FDA games looking into CEPH, Even with major political pressures they got turned down. But soon, very soon another company is going to come out with a very similar drug.. which works well even better since the small companies drug, well.. not only did it not work, it killed them...



To: VLAD who wrote (11224)7/11/1998 12:16:00 PM
From: betty moyers  Read Replies (1) | Respond to of 23519
 
On milestone payments

I understand

Canada = $ 2 MM
ECU = $ 8 MM ( $ 2MM each for France, German, Italy, Spain)

That totals $10 MM

Someone gave future (but soon) country list as Mexico, Thailand, Taiwan, Hong Kong (as separate from China), China, Russia, and Middle East.

Do they get payments from any of these?

I am confused about Mexico as L.Wilson said (in CC) that they are already in Mexico going head to head with Viagra and doing well.

Is it right that agreements with J&J and Astra are different. That some countries they get milestone payments and paid for product. Other countries they are on a royalty basis?

Could someone clarify this situation please